Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference30 articles.
1. Centers for Disease Control and Prevention. Myeloma. https://www.cdc.gov/cancer/myeloma/index.htm. Accessed 1 Apr 2021.
2. American Cancer Society. Key statistics about multiple myeloma. 2022. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html. Accessed 24 May, 2022.
3. Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma [published correction appears in Haematologica. 2016 Aug;101(8):995]. Haematologica. 2016;101(4):396–406. https://doi.org/10.3324/haematol.2015.129189.
4. Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204–15.
5. Felber G, Chen C-C, Willson J, Bell C, Simard E, Nunna S, et al. US cost burden of relapsed refractory multiple myeloma during third and later lines of treatment. Blood. 2019;134(Suppl 1):4725. https://doi.org/10.1182/blood-2019-130791.